CADTH Canadian Drug Expert Committee recommendation: Nusinersen (Spinraza -- Biogen Canada Inc.) indication : treatment of 5q spinal muscular atrophy
The CADTH Canadian Drug Expert Committee (CDEC) recommends that nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA)
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, December 2017
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA) |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (9 pages) |